Jazz Pharmaceuticals PLC Form 4 insider transactions

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, received 2,987 restricted stock units on March 1, 2024, under the company's 2011 Equity Incentive Plan.

Samantha Pearce, SVP, Head of Europe & International at Jazz Pharmaceuticals, reports acquisition and disposal of ordinary shares.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the acquisition of 12,348 ordinary shares and subsequent holdings of 45,061 shares.

EVP, Global Head of R&D at Jazz Pharmaceuticals, Robert Iannone, reports acquisition of 16,928 ordinary shares and disposal of shares on March 1, 2024.

Renee D Gala, President & COO of Jazz Pharmaceuticals, reports the acquisition of 19,916 ordinary shares and a grant of restricted stock units.

Bruce Cozadd, Chairman & CEO of Jazz Pharmaceuticals, reports the acquisition of restricted stock units under the company's 2011 Equity Incentive Plan.

Director Patrick Kennedy reports acquiring 1,423 shares of Jazz Pharmaceuticals common stock on March 1, 2024, through restricted stock units.

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals, reports the acquisition of ordinary shares, including restricted stock units, in a recent SEC Form 4 filing.